Beam Therapeutics Management
Management criteria checks 3/4
Beam Therapeutics' CEO is John Evans, appointed in Jan 2017, has a tenure of 9.17 years. total yearly compensation is $6.41M, comprised of 11.2% salary and 88.8% bonuses, including company stock and options. directly owns 0.92% of the company’s shares, worth $24.20M. The average tenure of the management team and the board of directors is 5.6 years and 5.2 years respectively.
Key information
John Evans
Chief executive officer
US$6.4m
Total compensation
| CEO salary percentage | 11.17% |
| CEO tenure | 9.2yrs |
| CEO ownership | 0.9% |
| Management average tenure | 5.6yrs |
| Board average tenure | 5.2yrs |
Recent management updates
Recent updates
Beam Therapeutics: Great Potential, But Patience Is Needed
Feb 27
Base Editing Platform And PKU Umbrella Trials Will Struggle To Justify Long Runway
Catalysts About Beam Therapeutics Beam Therapeutics develops base editing genetic medicines that aim to provide onetime treatments for serious diseases such as sickle cell disease, alpha-1 antitrypsin deficiency and phenylketonuria. What are the underlying business or industry changes driving this perspective?
The "Molecular Pencil": Why Beam's Technology is Built to Win
The "Molecular Pencil": Why Beam's Technology is Built to Win The investment thesis in Beam Therapeutics is a long-term, high-conviction bet on a fundamental technological shift in genetic medicine. While first-generation gene editors like CRISPR-Cas9 function as "molecular scissors," they are an inherently disruptive tool.Is Beam Therapeutics (NASDAQ:BEAM) In A Good Position To Invest In Growth?
Jul 23
Shareholders May Find It Hard To Justify Increasing Beam Therapeutics Inc.'s (NASDAQ:BEAM) CEO Compensation For Now
May 29
Advancing BEAM-101 And BEAM-302 Will Transform Treatment Of Hematology And Liver Genetic Diseases
Promising programs in genetic diseases and innovative technology could significantly boost market share and revenue potential.Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy
Mar 21Beam Therapeutics: Single-Base Editing Seems To Work
Mar 10Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares
Jan 31Beam Therapeutics: Too Expensive For Me, But Watch For Important Catalysts
Jan 22Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation
Dec 20Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch
Nov 07Insufficient Growth At Beam Therapeutics Inc. (NASDAQ:BEAM) Hampers Share Price
Oct 28Beam Therapeutics: Still Holding Fast To Generous Valuation, Still Not A Buy
Sep 29We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn
Sep 04Beam Therapeutics Inc.'s (NASDAQ:BEAM) Prospects Need A Boost To Lift Shares
Jul 12Beam Therapeutics: Slow Developmental Progress, But Promising Potential
Jul 01We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn
May 13Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects
Apr 24Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S
Apr 07Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 01Things Look Grim For Beam Therapeutics Inc. (NASDAQ:BEAM) After Today's Downgrade
Feb 29Beam Therapeutics: Cool Tech, But At A Way Inflated Price For Now
Feb 08This Just In: Analysts Are Boosting Their Beam Therapeutics Inc. (NASDAQ:BEAM) Outlook for This Year
Nov 01CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | -US$80m |
| Sep 30 2025 | n/a | n/a | -US$415m |
| Jun 30 2025 | n/a | n/a | -US$399m |
| Mar 31 2025 | n/a | n/a | -US$387m |
| Dec 31 2024 | US$6m | US$716k | -US$377m |
| Sep 30 2024 | n/a | n/a | -US$144m |
| Jun 30 2024 | n/a | n/a | -US$143m |
| Mar 31 2024 | n/a | n/a | -US$135m |
| Dec 31 2023 | US$6m | US$685k | -US$133m |
| Sep 30 2023 | n/a | n/a | -US$314m |
| Jun 30 2023 | n/a | n/a | -US$327m |
| Mar 31 2023 | n/a | n/a | -US$316m |
| Dec 31 2022 | US$9m | US$650k | -US$289m |
| Sep 30 2022 | n/a | n/a | -US$315m |
| Jun 30 2022 | n/a | n/a | -US$234m |
| Mar 31 2022 | n/a | n/a | -US$238m |
| Dec 31 2021 | US$14m | US$590k | -US$371m |
| Sep 30 2021 | n/a | n/a | -US$401m |
| Jun 30 2021 | n/a | n/a | -US$408m |
| Mar 31 2021 | n/a | n/a | -US$366m |
| Dec 31 2020 | US$907k | US$529k | -US$196m |
| Sep 30 2020 | n/a | n/a | -US$132m |
| Jun 30 2020 | n/a | n/a | -US$119m |
| Mar 31 2020 | n/a | n/a | -US$106m |
| Dec 31 2019 | US$2m | US$473k | -US$91m |
Compensation vs Market: John's total compensation ($USD6.41M) is about average for companies of similar size in the US market ($USD6.87M).
Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.
CEO
John Evans (47 yo)
Mr. John M. Evans, M.B.A., is CEO & Director of Beam Therapeutics Inc. from January 2017. He joined the Beam Therapeutics Inc. in 2017. He was President, CEO & Director of Beam Therapeutics Inc. until Janu...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 9.2yrs | US$6.41m | 0.92% $ 24.2m | |
| President | 6.2yrs | US$3.38m | 0.12% $ 3.1m | |
| Chief Financial Officer | 1.3yrs | US$5.42m | 0.014% $ 363.7k | |
| Senior VP | 6.9yrs | US$2.58m | 0.043% $ 1.1m | |
| Chief Medical Officer | 5yrs | US$2.62m | 0.0018% $ 46.1k | |
| Co-Founder | no data | no data | no data | |
| Co-Founder | no data | no data | no data | |
| Co-Founder | no data | no data | no data | |
| Senior VP of Finance | no data | no data | 0.0062% $ 164.2k | |
| Chief Technology Officer | no data | no data | no data | |
| Chief Scientific Officer | 3yrs | no data | no data | |
| Vice President of Investor Relations & External Communications | no data | no data | no data |
Experienced Management: BEAM's management team is seasoned and experienced (5.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 9.2yrs | US$6.41m | 0.92% $ 24.2m | |
| Independent Director | 4.3yrs | US$447.04k | 0% $ 0 | |
| Independent Lead Director | 7.8yrs | US$485.20k | 0.017% $ 451.2k | |
| Independent Director | 6.4yrs | US$450.24k | 0% $ 0 | |
| Independent Director | 5.2yrs | US$447.74k | 0% $ 0 | |
| Independent Director | 1.3yrs | US$774.60k | no data | |
| Independent Director | 2.3yrs | US$444.39k | 0% $ 0 |
Experienced Board: BEAM's board of directors are considered experienced (5.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/09 14:37 |
| End of Day Share Price | 2026/03/06 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Beam Therapeutics Inc. is covered by 22 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| William Pickering | Bernstein |
| Alec Stranahan | BofA Global Research |
| Whitney Ijem | Canaccord Genuity |